Educational content only. This post explains how financial concepts and published data apply generally to healthcare practices — it does not constitute advice for your specific situation. Consult your accountant, lender, and relevant advisors before making any significant business or financial decisions.
Medical aesthetics is one of the fastest-growing segments of the North American healthcare services market by most published measures. It's also one of the most financially distinct — with a cost and revenue structure that doesn't map neatly onto the assumptions operators carry from other healthcare backgrounds.
The Revenue Model
Published AmSpa State of the Industry data — the most comprehensive industry survey for US medical spas — describes average annual revenue for established US medical spa practices above $1,000,000, with top-performing practices substantially higher. Published data describes average revenue per treatment visit well above most other clinic types, reflecting the out-of-pocket payment model and the procedure pricing that the absence of insurance scheduling enables.
Unlike most healthcare clinic types in both Canada and the US, medical aesthetics does not involve provincial health billing or insurance reimbursement for cosmetic services. Revenue is predominantly direct-pay at the practice's own fee schedule. This produces a fundamentally different revenue model — higher revenue per visit, no billing lag, no insurance write-off — and a different patient acquisition model, because there's no insurance directory or referral network equivalent to drive patient flow.
Published AmSpa data describes two primary revenue model structures:
- Transaction-based revenue — individual treatment bookings. Published resources note this creates revenue variability with seasonal patterns.
- Membership and package revenue — prepaid packages and membership programs. Published resources describe these as associated with higher client retention and more predictable revenue, at the cost of front-loading payment and managing redemption.
The Cost Structure — What Makes It Different
Consumable costs are higher relative to revenue than most clinic types. Published resources describe injectables — neuromodulators and dermal fillers specifically — as having significant per-unit costs relative to treatment revenue. Published AmSpa data describes consumable costs, including injectables, as one of the three primary overhead drivers alongside staff and equipment. Practices with high injectable volume carry consumable costs as a percentage of revenue that a physiotherapy or chiropractic practice doesn't experience.
Equipment capital requirements vary enormously by service mix. Published equipment cost ranges describe laser, energy, and body contouring platforms from under $50,000 for entry-level single platforms to several hundred thousand dollars for multi-platform setups. Published resources in both Canada and the US note that technology in this sector evolves rapidly — platform obsolescence is a real planning consideration in a way it isn't for clinical equipment with 15-year useful lives.
Equipment leasing is particularly common in medical aesthetics for this reason. A 3-year lease on a laser platform transfers the residual value risk to the lessor — relevant when the platform's competitive position may change before its end of useful life. Published resources describe this trade-off as specific to technology-intensive aesthetics equipment rather than general clinical equipment.
Medical oversight is both a regulatory requirement and an ongoing cost. Published regulatory guidance from provincial bodies in Canada (CPSO in Ontario, CPSBC in BC, CPSA in Alberta) and state medical/nursing boards in the US describes oversight requirements for injectable and energy-based treatments that vary by jurisdiction. Medical director agreements — required in most Canadian and US markets for clinic operation — represent a recurring cost that affects the overhead structure. This cost is not present in most other clinic types.
Regulatory Context Differs Materially by Market
Published guidance from Canadian provincial regulatory bodies describes requirements specific to each province. CPSO guidance in Ontario, CPSBC guidance in BC, and CPSA guidance in Alberta all describe oversight requirements for controlled acts including injectable treatments. Published resources consistently note these requirements are evolving and jurisdiction-specific.
Published AmSpa resources describe US regulation as varying substantially by state — some states permit certain injectable treatments by RNs or NPs under general supervision, while others require physician presence for specific procedures. Published AmSpa guidance includes state-specific regulatory summaries that are updated as regulation changes.
The regulatory compliance structure has direct business model implications in both markets — it determines what services can be offered, how the medical director relationship is structured, and what the staffing model looks like. These are not purely operational questions; they affect the cost structure directly.
What Published Profitability Data Describes
Published AmSpa data describes significant variation in net margin outcomes across US medical spa practices, with staff costs, consumables, and equipment-related costs identified as the three primary overhead drivers. Canadian market data is less consolidated but published global aesthetic industry reports describe similar structural cost characteristics across North American markets.
Published resources note that medical spa profitability is more sensitive to the service mix than most clinic types — a practice heavily weighted toward injectable treatments has a fundamentally different consumable cost structure than one weighted toward energy-based procedures. The business model decision about service mix is also, necessarily, a financial model decision.
→ See also: Equipment Leasing vs. Buying for Clinics
Equipment leasing is one of three structures clinic operators use to finance clinical equipment — alongside outright purchase and term loans. Each produces a different monthly cash obligation, balance sheet profile, and total cost of ownership.
See how the scenarios compare in the Capital Structure Tool →Model medical spa startup costs for both Canadian and US markets — with equipment tier, build intensity, and ramp-adjusted break-even. Costs vary significantly by service mix — injection-focused versus device-heavy practices should adjust equipment inputs accordingly.
Estimate Your Startup Costs →Disclaimer: All figures referenced are from published industry sources and represent general patterns — not estimates for any specific practice. KlinDeck is not a financial advisor, accountant, lender, or lawyer. Tools are educational references only. Consult qualified professionals before making significant decisions.